Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2008 (2008), Article ID 891425, 13 pages
http://dx.doi.org/10.1155/2008/891425
Review Article

Should We Use PPAR Agonists to Reduce Cardiovascular Risk?

Departments of Epidemiology & Medicine, University of Iowa, Iowa City 52242, IA, USA

Received 2 July 2007; Accepted 9 October 2007

Academic Editor: Giulia Chinetti

Copyright © 2008 Jennifer G. Robinson. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. M. Evans, G. D. Barish, and Y.-X. Wang, “PPARs and the complex journey to obesity,” Journal of Nature Medicine, vol. 10, no. 4, pp. 355–361, 2004. View at PublisherView at Google ScholarView at PubMed
  2. B. V. Howard, B. L. Rodriguez, and P. H. Bennett et al., “Prevention conference vi: diabetes and cardiovascular disease: writing group I: epidemiology,” Circulation, vol. 105, no. 18, pp. e132–137, 2002. View at PublisherView at Google Scholar
  3. S. M. Grundy, “Small LDL, atherogenic dyslipidemia, and the metabolic syndrome,” Circulation, vol. 95, no. 1, pp. 1–4, 1997.
  4. P. Lefebvre, G. Chinetti, J.-C. Fruchart, and B. Staels, “Sorting out the roles of PPAR γ in energy metabolism and vascular homeostasis,” Journal of Clinical Investigation, vol. 116, no. 3, pp. 571–580, 2006. View at PublisherView at Google Scholar
  5. R. K. Semple, V. K. K. Chatterjee, and S. O'Rahilly, “PPARα and human metabolic disease,” Journal of Clinical Investigation, vol. 116, no. 3, pp. 581–589, 2006. View at PublisherView at Google ScholarView at PubMed
  6. G. D. Barish, V. A. Narkar, and R. M. Evans, “PPARδ: a dagger in the heart of the metabolic syndrome,” Journal of Clinical Investigation, vol. 116, no. 3, pp. 590–597, 2006. View at PublisherView at Google Scholar
  7. Y.-X. Wang, C.-H. Lee, and S. Tiep et al., “Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity,” Cell, vol. 113, no. 2, pp. 159–170, 2003. View at PublisherView at Google Scholar
  8. H. B. Rubins, S. J. Robins, and D. Collins et al., “Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol,” New England Journal of Medicine, vol. 341, no. 6, pp. 410–418, 1999. View at PublisherView at Google ScholarView at PubMed
  9. M. H. Frick, O. Elo, and K. Haapa, “Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia.safety of treatment, changes in risk factors, and incidence of coronary heart disease,” New England Journal of Medicine, vol. 317, no. 20, pp. 1237–1245, 1987.
  10. S. Behar, D. Brunner, E. Kaplinsky, L. Mandelzweig, and M. Benderly, “Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the bezafibrate infarction prevention (BIP) study,” Circulation, vol. 102, no. 1, pp. 21–27, 2000.
  11. A. Keech, R. J. Simes, and P. Parter et al., “Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial,” Lancet, vol. 366, no. 9500, pp. 1849–1861, 2005. View at PublisherView at Google ScholarView at PubMed
  12. S. J. Robins, D. Collins, and J. T. Wittes et al., “Relation of gemfibrozil treatment and lipid levels with major coronary events. VA-HIT: a randomized controlled trial,” Journal of the American Medical Association, vol. 285, no. 12, pp. 1585–1591, 2001. View at PublisherView at Google Scholar
  13. J. G. Robinson, B. Smith, N. Maheshwari, and H. Schrott, “Pleiotropic effects of statins: benefit beyond cholesterol reduction? a meta-regression analysis,” Journal of the American College of Cardiology, vol. 46, no. 10, pp. 1855–1862, 2005. View at PublisherView at Google ScholarView at PubMed
  14. D. J. Gordon, J. L. Probstfield, and R. J. Garrison et al., “High-density lipoprotein cholesterol and cardiovascular disease. four prospective american studies,” Circulation, vol. 79, no. 1, pp. 8–15, 89.
  15. A. Tenenbaum, M. Motro, and E. Z. Fisman, “Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons,” Cardiovascular Diabetology, vol. 4, 2005. View at PublisherView at Google ScholarView at PubMed
  16. G. Steiner, A. Hamsten, and J. Hosking et al., “Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the diabetes atherosclerosis intervention study, a randomised study,” Lancet, vol. 357, no. 9260, pp. 905–910, 2001. View at PublisherView at Google Scholar
  17. Coronary Drug Project, “Clofibrate and niacin in coronary heart disease,” Journal of American Medical Association, vol. 231, no. 4, pp. 360–380, 1975. View at PublisherView at Google Scholar
  18. M. Oliver, “A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. report from the committee of principal investigators,” British Heart Journal, vol. 40, no. 10, pp. 1069–1118, 1978. View at PublisherView at Google Scholar
  19. M. H. Frick, O. P. Heinonen, J. K. Huttunen, P. Koskinen, M. Mänttäri, and V. Manninen, “Efficacy of gemfibrozil in dyslipidaemic subjects with suspected heart disease. an ancillary study in the Helsinki Heart Study frame population,” Annals of Medicine, vol. 25, no. 1, pp. 41–45, 1993. View at PublisherView at Google Scholar
  20. C. Baigent, A. Keech, and P. M. Kearney et al., “Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins,” Lancet, vol. 366, no. 9493, pp. 1267–1278, 2005. View at PublisherView at Google ScholarView at PubMed
  21. L. Tenkanen, M. Mänttäri, P. T. Kovanen, H. Virkkunen, and V. Manninen, “Gemfibrozil in the treatment of dyslipidemia: an 18-year mortality follow-up of the Helsinki Heart Study,” Archives of Internal Medicine, vol. 166, no. 7, pp. 743–748, 2006. View at PublisherView at Google ScholarView at PubMed
  22. J. K. Huttunen, O. P. Heinonen, and V. Manninen et al., “The helsinki heart study: an 8.5-year safety and mortality follow-up,” Journal of Internal Medicine, vol. 235, no. 1, pp. 31–39, 1994.
  23. H. B. Rubins, S. J. Robins, and D. Collins et al., “Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs High-density Lipoprotein Intervention Trial (VA-HIT),” Archives of Internal Medicine, vol. 162, no. 22, pp. 2597–2604, 2002. View at PublisherView at Google Scholar
  24. S. Westphal, J. Dierkes, and C. Luley, “Effects of fenofibrate and gemfibrozil on plasma homocysteine,” Lancet, vol. 358, no. 9275, pp. 39–40, 2001. View at PublisherView at Google ScholarView at PubMed
  25. M. H. Davidson, A. Armani, J. M. McKenney, and T. A. Jacobson, “Safety considerations with fibrate therapy,” American Journal of Cardiology, vol. 99, no. 6, suppl. 1, pp. S3–S18, 2007. View at PublisherView at Google ScholarView at PubMed
  26. G. Luc, N. Jacob, M. Bouly, J.-C. Fruchart, B. Staels, and P. Giral, “Fenofibrate increases homocystinemia through a PPARα-mediated mechanism,” Journal of Cardiovascular Pharmacology, vol. 43, no. 3, pp. 452–453, 2004. View at PublisherView at Google Scholar
  27. O. Mayer Jr., J. Šimon, L. Holubec, R. Pikner, and I. Šubrt, “Fenofibrate-induced hyperhomocysteinemia may be prevented by folate co-administration,” European Journal of Clinical Pharmacology, vol. 59, no. 5-6, pp. 367–371, 2003. View at PublisherView at Google ScholarView at PubMed
  28. S. Kaul, A. A. Zadeh, and P. K. Shah, “Homocysteine hypothesis for atherothrombotic cardiovascular disease. not validated,” Journal of the American College of Cardiology, vol. 48, no. 5, pp. 914–923, 2006. View at PublisherView at Google ScholarView at PubMed
  29. C. Hottelart, N. El Esper, F. Rose, J. M. Achard, and A. Fournier, “Fenofibrate increases creatininemia by increasing metabolic production of creatinine,” Nephron, vol. 92, no. 3, pp. 536–541, 2002. View at PublisherView at Google Scholar
  30. S. M. Grundy, J. I. Cleeman, and C. N. Bairey Merz et al., “Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment panel III guidelines,” Circulation, vol. 110, no. 2, pp. 227–239, 2004. View at PublisherView at Google ScholarView at PubMed
  31. J. B. Buse, “Action to control cardiovascular risk in diabetes (ACCORD) trial: design and methods,” American Journal of Cardiology, vol. 99, no. 12, suppl. 1, pp. S21–S33, 2007. View at PublisherView at Google ScholarView at PubMed
  32. A. Keech, J. Simes, P. Barter, J. Best, R. Scott, and M.-R. Taskinen, “Correction to the field study report,” Lancet, vol. 368, no. 9545, p. 1415, 2006. View at PublisherView at Google ScholarView at PubMed
  33. P. H. Jones, M. H. Davidson, and E. A. Stein et al., “Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR trial),” American Journal of Cardiology, vol. 92, no. 2, pp. 152–160, 2003. View at PublisherView at Google Scholar
  34. P. H. Jones and M. H. Davidson, “Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin,” American Journal of Cardiology, vol. 95, no. 1, pp. 120–122, 2005. View at PublisherView at Google ScholarView at PubMed
  35. D. J. Graham, J. A. Staffa, and D. Shatin et al., “Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs,” Journal of the American Medical Association, vol. 292, no. 21, pp. 2585–2590, 2004. View at PublisherView at Google ScholarView at PubMed
  36. National Cholesterol Education Panel, “Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report,” Circulation, vol. 106, no. 25, pp. 3143–3421, 2002.
  37. J. G. Robinson and N. J. Stone, “Antiatherosclerotic and antithrombotic effects of omega-3 fatty acids,” American Journal of Cardiology, vol. 98, no. 4, suppl. 1, pp. 39–49, 2006. View at PublisherView at Google ScholarView at PubMed
  38. C. Wang, W. S. Harris, and M. Chung et al., “N-3 fatty acids from fish or fish-oil supplements, but not α-linolenic acid, benefit cardiovascular disease outcomes in primary- and secondary-prevention studies: a systematic review,” American Journal of Clinical Nutrition, vol. 84, no. 1, pp. 5–17, 2006.
  39. J. M. McKenney, M. Farnier, and K.-W. Lo et al., “Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia,” Journal of the American College of Cardiology, vol. 47, no. 8, pp. 1584–1587, 2006. View at PublisherView at Google ScholarView at PubMed
  40. J. A. Dormandy, B. Charbonnel, and D. J. Eckland et al., “Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial in macroVascular Events): a randomised controlled trial,” Lancet, vol. 366, no. 9493, pp. 1279–1289, 2005. View at PublisherView at Google ScholarView at PubMed
  41. E. Selvin, S. Marinopoulos, and G. Berkenblit et al., “Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus,” Annals of Internal Medicine, vol. 141, no. 6, pp. 421–431, 2004.
  42. J. H. Tanne, “FDA places “black box” warning on antidiabetes drugs,” British Medical Journal, vol. 334, no. 7606, p. 1237, 2007. View at PublisherView at Google ScholarView at PubMed
  43. R. W. Nesto, D. Bell, and R. O. Bonow et al., “Thiazolidinedione use, fluid Retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association,” Circulation, vol. 108, no. 23, pp. 2941–2948, 2003. View at PublisherView at Google ScholarView at PubMed
  44. H. J. Dargie, P. R. Hildebrandt, and G. A. J. Riegger et al., “A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association Functional Class I or II Heart Failure,” Journal of the American College of Cardiology, vol. 49, no. 16, pp. 1696–1704, 2007. View at PublisherView at Google ScholarView at PubMed
  45. Takeda Pharmaceuticals, “Actos [piogltiazone hydrochloride] prescribing information,” 2007, http://www.actos.com/actospro/prescribniginto.aspx.
  46. GlaxoSmithKline, “Avandia (rosiglitazone maleate) [prescribing information],” 2007, http://us.gsk.com/products/assets/us_avandia.pdf.
  47. S. E. Nissen and K. Wolski, “Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes,” New England Journal of Medicine, vol. 356, no. 24, pp. 2457–2471, 2007. View at PublisherView at Google ScholarView at PubMed
  48. B. M. Psaty and C. D. Furberg, “Rosiglitazone and cardiovascular risk,” New England Journal of Medicine, vol. 356, no. 24, pp. 2522–2524, 2007. View at PublisherView at Google ScholarView at PubMed
  49. S. E. Kahn, S. M. Haffner, and M. A. Heise et al., “Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy,” New England Journal of Medicine, vol. 355, no. 23, pp. 2427–2443, 2006. View at PublisherView at Google ScholarView at PubMed
  50. H. C. Gerstein, S. Yusuf, and J. Bosch et al., “Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial,” Lancet, vol. 368, no. 9541, pp. 1096–1105, 2006. View at PublisherView at Google ScholarView at PubMed
  51. P. D. Home, S. J. Pocock, and H. Beck-Nielsen et al., “Rosiglitazone evaluated for cardiovascular outcomes—an interim analysis,” New England Journal of Medicine, vol. 357, no. 1, pp. 28–38, 2007. View at PublisherView at Google ScholarView at PubMed
  52. R. B. Goldberg, D. M. Kendall, and M. A. Deeg et al., “A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia,” Diabetes Care, vol. 28, no. 7, pp. 1547–1554, 2005. View at PublisherView at Google Scholar
  53. A. T. McAfee, C. Koro, J. Landon, N. Ziyadeh, and A. M. Walker, “Coronary heart disease outcomes in patients receiving antidiabetic agents,” Pharmacoepidemiology and Drug Safety, vol. 16, no. 7, pp. 711–725, 2007. View at PublisherView at Google ScholarView at PubMed
  54. K. H. Kahler, M. Rajan, and G. G. Rhoads et al., “Impact of oral antihyperglycemic therapy on all-cause mortality among patients with diabetes in the veterans health administration,” Diabetes Care, vol. 30, no. 7, pp. 1689–1693, 2007. View at PublisherView at Google ScholarView at PubMed
  55. M. F. Magee and W. L. Isley, “Rationale, design, and methods for Glycemic Control in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial,” American Journal of Cardiology, vol. 97, no. 12, suppl. 1, pp. 20–30, 2006. View at PublisherView at Google ScholarView at PubMed
  56. C. Abraira, W. Duckworth, and M. McCarren et al., “Design of the cooperative study on glycemic control and complications in diabetes mellitus type 2: veterans affairs diabetes trial,” Journal of Diabetes and Its Complications, vol. 17, no. 6, pp. 314–322, 2003. View at PublisherView at Google Scholar
  57. M. Hanefeld, N. Marx, and A. Pfützner et al., “Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein. the PIOSTAT study,” Journal of the American College of Cardiology, vol. 49, no. 3, pp. 290–297, 2007. View at PublisherView at Google ScholarView at PubMed
  58. H. C. Gerstein, M. C. Riddle, and D. M. Kendall et al., “Glycemia treatment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial,” American Journal of Cardiology, vol. 99, no. 12, suppl. 1, pp. 34–43, 2007. View at PublisherView at Google ScholarView at PubMed
  59. T. Hampton, “Diabetes drugs tied to fractures in women,” Journal of the American Medical Association, vol. 297, no. 15, p. 1645, 2007. View at PublisherView at Google ScholarView at PubMed
  60. H. P. Koeffler, “Peroxisome proliferator-activated receptor γ and cancers,” Clinical Cancer Research, vol. 9, no. 1 I, pp. 1–9, 2003.
  61. E. Erdmann, J. A. Dormandy, B. Charbonnel, M. Massi-Benedetti, I. K. Moules, and A. M. Skene, “The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction. results from the PROactive (PROactive 05) study,” Journal of the American College of Cardiology, vol. 49, no. 17, pp. 1772–1780, 2007. View at PublisherView at Google ScholarView at PubMed
  62. R. Wilcox, M.-G. Bousser, and D. J. Betteridge et al., “Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: Results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04),” Stroke, vol. 38, no. 3, pp. 865–873, 2007. View at PublisherView at Google ScholarView at PubMed
  63. D. M. Nathan, J. B. Buse, and M. B. Davidson et al., “Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. a consensus statement from the american diabetes association and the european association for the study of diabetes,” Diabetes Care, vol. 29, no. 8, pp. 1963–1972, 2006. View at PublisherView at Google ScholarView at PubMed
  64. C. Fiévet, J.-C. Fruchart, and B. Staels, “PPARα and PPAR γ dual agonists for the treatment of type 2 diabetes and the metabolic syndrome,” Current Opinion in Pharmacology, vol. 6, no. 6, pp. 606–614, 2006. View at PublisherView at Google ScholarView at PubMed
  65. S. E. Nissen, K. Wolski, and E. J. Topol, “Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus,” Journal of the American Medical Association, vol. 294, no. 20, pp. 2581–2586, 2005. View at PublisherView at Google ScholarView at PubMed
  66. D. M. Kendall, C. J. Rubin, and P. Mohideen et al., “Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (α/γ peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a double-blind, randomized, pioglitazone-comparative study,” Diabetes Care, vol. 29, no. 5, pp. 1016–1023, 2006. View at PublisherView at Google ScholarView at PubMed
  67. G. Boden, C. Homko, M. Mozzoli, M. Zhang, K. Kresge, and P. Cheung, “Combined use of rosiglitazone and fenofibrate in patients with type 2 diabetes: prevention of fluid retention,” Diabetes Care, vol. 56, no. 1, pp. 248–255, 2007. View at PublisherView at Google ScholarView at PubMed
  68. B. Fagerberg, S. Edwards, and T. Halmos et al., “Tesaglitazar, a novel dual peroxisome proliferator-activated receptor α/γ agonist, dose-dependently improves the metabolic abnormalities associated with insulin resistance in a non-diabetic population,” Diabetologia, vol. 48, no. 9, pp. 1716–1725, 2005. View at PublisherView at Google ScholarView at PubMed
  69. B. K. Skrumsager, K. K. Nielsen, M. Müller, G. Pabst, P. G. Drake, and B. Edsberg, “Ragaglitazar: the pharmacokinetics, pharmacodynamics, and tolerability of a novel dual PPARα and γ agonist in healthy subjects and patients with type 2 diabetes,” Journal of Clinical Pharmacology, vol. 43, no. 11, pp. 1244–1256, 2003. View at PublisherView at Google ScholarView at PubMed
  70. L. Hansen, C. T. Ekstrøm, R. T. Y. Palacios, M. Anant, K. Wassermann, and R. R. Reinhardt, “The Pro12Ala variant of the PPARG gene is a risk factor for peroxisome proliferator-activated receptor-γ/α agonist-induced edema in type 2 diabetic patients,” Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 9, pp. 3446–3450, 2006. View at PublisherView at Google ScholarView at PubMed
  71. H. Duez, B. Lefebvre, and P. Poulain et al., “Regulation of human ApoA-I by gemfibrozil and fenofibrate through selective peroxisome proliferator-activated receptor α modulation,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 25, no. 3, pp. 585–591, 2005. View at PublisherView at Google ScholarView at PubMed
  72. H. S. Camp, O. Li, and S. C. Wise et al., “Differential activation of peroxisome proliferator-activated receptor-γ by troglitazone and rosiglitazone,” Diabetes, vol. 49, no. 4, pp. 539–547, 2000. View at PublisherView at Google Scholar
  73. F. Chang, L. A. Jaber, H. D. Berlie, and M. B. O'Connell, “Evolution of peroxisome proliferator-activated receptor agonists,” Annals of Pharmacotherapy, vol. 41, no. 6, pp. 973–983, 2007. View at PublisherView at Google ScholarView at PubMed
  74. S.-Y. Park, Y.-R. Cho, and B. N. Finck et al., “Cardiac-specific overexpression of peroxisome proliferator-activated receptor- α causes insulin resistance in heart and liver,” Diabetes, vol. 54, no. 9, pp. 2514–2524, 2005. View at PublisherView at Google Scholar
  75. D. L. Sprecher, C. Massien, and G. Pearce et al., “Triglyceride: high-density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor δ agonist,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 27, no. 2, pp. 359–365, 2007. View at PublisherView at Google ScholarView at PubMed
  76. V. Manninen, M. O. Elo, and M. H. Frick et al., “Lipid alterations and decline in the incidence of coronary heart disease in the helsinki heart study,” Journal of the American Medical Association, vol. 260, no. 5, pp. 641–651, 1988. View at PublisherView at Google Scholar
  77. P. D. Home, S. J. Pocock, and H. Beck-Nielsen et al., “Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol,” Diabetologia, vol. 48, no. 9, pp. 1726–1735, 2005. View at PublisherView at Google ScholarView at PubMed